PMID- 30084335
OWN - NLM
STAT- MEDLINE
DCOM- 20190821
LR  - 20210504
IS  - 2212-3938 (Electronic)
IS  - 1574-8847 (Linking)
VI  - 13
IP  - 4
DP  - 2018
TI  - SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the 
      Literature.
PG  - 261-272
LID - 10.2174/1574884713666180807150509 [doi]
AB  - BACKGROUND: Sodium-Glucose Cotransporter 2 (SGTL-2) inhibitors are a new class of 
      antidiabetics, which have been approved for the treatment of patients with Type 2 
      Diabetes Mellitus (T2DM). Besides their beneficial metabolic effects, they exert 
      favourable results in cardiovascular events and risk factors along with 
      renoprotection. However, SGLT-2 inhibitors have not been yet approved as an 
      adjunct therapy to insulin in patients with Type 1 Diabetes Mellitus (T1DM). This 
      review aims at presenting both clinical and experimental data that reinforce the 
      role of SGLT-2 inhibitors as adjunctive treatment in patients with T1DM along 
      with the main restrictions of their use, namely Diabetic Ketoacidosis (DKA). 
      METHODS: We conducted a comprehensive research of the relevant literature 
      regarding the off-label use of SGLT-2 inhibitors in clinical practice, presenting 
      the major benefits and the potential risks. RESULTS: SGLT-2 inhibitors are 
      associated with improved glycemic control, reduction in body weight, and decrease 
      in insulin dosage, along with their beneficial cardiovascular and renal effects. 
      However, we cannot overlook the association with increased incidence of DKA 
      events, in the presence of well known predisposing factors. Further investigation 
      is required, in order to establish them as adjunctive treatment in those 
      patients. CONCLUSION: This novel class of antidiabetics seems to be a very 
      attractive treatment option in patients with T1DM, due to their multiple 
      beneficial effects, but the increased risk of DKA should be taken into account.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Patoulias, Dimitrios
AU  - Patoulias D
AD  - Second Propedeutic Department of Internal Medicine, Hippokration Hospital of 
      Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Imprialos, Konstantinos
AU  - Imprialos K
AD  - Second Propedeutic Department of Internal Medicine, Hippokration Hospital of 
      Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Stavropoulos, Konstantinos
AU  - Stavropoulos K
AD  - Second Propedeutic Department of Internal Medicine, Hippokration Hospital of 
      Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Athyros, Vasilios
AU  - Athyros V
AD  - Second Propedeutic Department of Internal Medicine, Hippokration Hospital of 
      Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Doumas, Michael
AU  - Doumas M
AD  - Second Propedeutic Department of Internal Medicine, Hippokration Hospital of 
      Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
AD  - VAMC and George Washington University, Washington, DC, United States.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Clin Pharmacol
JT  - Current clinical pharmacology
JID - 101273158
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 1ULL0QJ8UC (dapagliflozin)
MH  - Benzhydryl Compounds/adverse effects/pharmacology/therapeutic use
MH  - Blood Glucose/*drug effects/metabolism
MH  - Diabetes Mellitus, Type 1/blood/*drug therapy
MH  - Diabetic Ketoacidosis/blood/chemically induced
MH  - Glucosides/adverse effects/pharmacology/therapeutic use
MH  - Humans
MH  - Randomized Controlled Trials as Topic/methods
MH  - *Sodium-Glucose Transporter 2/metabolism
MH  - Sodium-Glucose Transporter 2 Inhibitors/adverse effects/pharmacology/*therapeutic 
      use
OTO - NOTNLM
OT  - SGLT-2 inhibitors
OT  - canagliflozin
OT  - cardiovascular disease
OT  - dapagliflozin
OT  - empagliflozin
OT  - ketoacidosis
OT  - type 1 dabetes mellitus.
EDAT- 2018/08/08 06:00
MHDA- 2019/08/23 06:00
CRDT- 2018/08/08 06:00
PHST- 2017/11/21 00:00 [received]
PHST- 2018/07/10 00:00 [revised]
PHST- 2018/08/03 00:00 [accepted]
PHST- 2018/08/08 06:00 [pubmed]
PHST- 2019/08/23 06:00 [medline]
PHST- 2018/08/08 06:00 [entrez]
AID - CCP-EPUB-92240 [pii]
AID - 10.2174/1574884713666180807150509 [doi]
PST - ppublish
SO  - Curr Clin Pharmacol. 2018;13(4):261-272. doi: 10.2174/1574884713666180807150509.